Research Study

A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Pulmonary Fibrosis
ClinicalTrials.gov# 
NCT02538536
Status 
Closed to Recruitment
Study Start/End 
Sep 1, 2015 to Dec 31, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Giselle Gerdak, Research Coordinator
Phone 
604-875-5091
Purpose of Study 

This is a Phase 2, open-label, single-arm study of the safety and tolerability of PBI-4050 800 mg daily oral administration in 40 adult patients with IPF.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.